BioIVT is expanding its global commercial capabilities in response to growing demand for its biospecimens and specialized research services
WESTBURY, NY, US - Oct 25, 2018 - BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Alan Findlater to the newly-created role of chief commercial officer. In his new position, Mr. Findlater will be responsible for all of BioIVTs commercial activities, including global sales, marketing and customer service.
Alan is a visionary leader with the requisite knowledge and experience to help guide BioIVT on its rapid growth trajectory as we continue to be the trusted leader for biological products and services, said BioIVT Chief Executive Officer Jeffrey Gatz.
Alan has successfully built and led global sales, marketing and commercial operation teams at several major organizations, and his strong services sales background aligns closely with our recent acquisitions. Equally important, he shares BioIVTs commitment to excellent customer service and product quality. I am delighted to welcome Alan to our executive team.
BioIVT has acquired five companies - Asterand Bioscience, Qualyst Transporter Solutions, Optivia Biotechnology, Ascendance Biotechnology, and Clinical Trials Laboratory Services - since August 2017.
BioIVT is at an exciting inflection point in its development due to a surge in demand for its research models and services. For example, the healthcare industrys increasing focus on personalized medicine is resulting in a corresponding increase in patient screening and specimen inclusion/exclusion criteria for preclinical development. This is creating a need for more specialized biospecimens, with comprehensive clinical data, to test new drug candidates for safety and efficacy, said Mr. Findlater.
Mr. Findlater has more than 33 years experience in the pharmaceutical, medical device, and R&D services sectors. He was chief commercial officer at WIL Research Laboratories for more than five years before it was acquired by Charles River Laboratories in April 2016.
Mr. Findlater was appointed Charles Rivers executive director, global business development, safety assessment, discovery and research models post-acquisition and led the commercial integration of both WIL Research Laboratories and Agilux discovery services.
Prior to that, Mr. Findlater held several senior global management positions at Covance Laboratories Inc., culminating in global vice president of sales and client services Early Pharmaceutical Development.
Mr. Findlater has a bachelors degree in chemistry from the University of Strathclyde and a masters degree in business administration from the University of Warwick Business School, UK.
About BioIVT
BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and
in vitro
hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit
www.bioivt.com
or follow the company on Twitter
@BioIVT
.